DK1787658T3 - Formuleringer med forsinket frigørelse og indeholdende somatostatin-analoge væksthormoninhibitorer - Google Patents

Formuleringer med forsinket frigørelse og indeholdende somatostatin-analoge væksthormoninhibitorer

Info

Publication number
DK1787658T3
DK1787658T3 DK05077559.2T DK05077559T DK1787658T3 DK 1787658 T3 DK1787658 T3 DK 1787658T3 DK 05077559 T DK05077559 T DK 05077559T DK 1787658 T3 DK1787658 T3 DK 1787658T3
Authority
DK
Denmark
Prior art keywords
growth hormone
delayed
release formulations
formulations containing
hormone inhibitors
Prior art date
Application number
DK05077559.2T
Other languages
English (en)
Inventor
Paolo Mascagni
Original Assignee
Chemi Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chemi Spa filed Critical Chemi Spa
Application granted granted Critical
Publication of DK1787658T3 publication Critical patent/DK1787658T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/31—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
DK05077559.2T 2005-11-10 2005-11-10 Formuleringer med forsinket frigørelse og indeholdende somatostatin-analoge væksthormoninhibitorer DK1787658T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP05077559A EP1787658B1 (en) 2005-11-10 2005-11-10 Sustained release formulations of somatostatin analogue inhibitors of growth hormone

Publications (1)

Publication Number Publication Date
DK1787658T3 true DK1787658T3 (da) 2012-06-25

Family

ID=35840709

Family Applications (1)

Application Number Title Priority Date Filing Date
DK05077559.2T DK1787658T3 (da) 2005-11-10 2005-11-10 Formuleringer med forsinket frigørelse og indeholdende somatostatin-analoge væksthormoninhibitorer

Country Status (8)

Country Link
EP (1) EP1787658B1 (da)
AT (1) ATE549011T1 (da)
CY (1) CY1112857T1 (da)
DK (1) DK1787658T3 (da)
ES (1) ES2383303T3 (da)
PL (1) PL1787658T3 (da)
PT (1) PT1787658E (da)
SI (1) SI1787658T1 (da)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0602639D0 (en) * 2006-02-09 2006-03-22 Novartis Ag Organic compounds
CA2702940C (en) * 2007-12-03 2016-09-13 Andrea Vitali New non-selective somatostatin analogues
ITUB20160416A1 (it) * 2016-01-28 2017-07-28 Italfarmaco Spa Uso di una formulazione a lento rilascio di octreotide per la prevenzione della formazione di seroma

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3045135A1 (de) 1980-11-29 1982-06-09 Sandoz-Patent-GmbH, 7850 Lörrach Pharmazeutische kompositionen enthaltende bioabbaubare polymere
FR2537980B1 (fr) 1982-12-17 1986-12-19 Sandoz Sa Derives d'acides hydroxycarboxyliques oligomeres, leur preparation et leur utilisation
GB8318552D0 (en) 1983-07-08 1983-08-10 Sandoz Ltd Organic compounds
NL8701143A (nl) 1986-05-27 1987-12-16 Sandoz Ag Farmaceutische preparaten.
GB2193891B (en) 1986-08-18 1990-07-25 Sandoz Ltd Nasal pharmaceutical composition containing a somatostatin anologue.
NL194729C (nl) 1986-10-13 2003-01-07 Novartis Ag Werkwijze voor de bereiding van peptidealcoholen via vaste fase.
DE3822557C2 (de) 1987-07-10 1998-07-02 Ciba Geigy Ag Arzneimittel, enthaltend Somatostatine
US5538739A (en) 1989-07-07 1996-07-23 Sandoz Ltd. Sustained release formulations of water soluble peptides
MY108621A (en) 1990-08-01 1996-10-31 Novartis Ag Polylactide preparation and purification
GB9206736D0 (en) 1992-03-27 1992-05-13 Sandoz Ltd Improvements of organic compounds and their use in pharmaceutical compositions
SI9300468A (en) 1992-10-14 1994-06-30 Hoffmann La Roche Injectable composition for the sustained release of biologically active compounds
JPH08505367A (ja) 1992-10-16 1996-06-11 スミスクライン・ビーチャム・コーポレイション 医薬用エマルジョン組成物
WO1995000126A1 (en) 1993-06-22 1995-01-05 Sandoz Ltd. Surface-modified albumin microspheres and pharmaceutical compositions containing them
IL110787A0 (en) 1993-08-27 1994-11-11 Sandoz Ag Biodegradable polymer, its preparation and pharmaceutical composition containing it
EP0896544B1 (en) 1996-06-11 2003-02-26 Novartis AG Combination of a somatostatin analogue and a rapamycin
PT839525E (pt) 1996-10-31 2004-10-29 Takeda Chemical Industries Ltd Preparacao de libertacao prolongada
CA2306090A1 (en) * 1997-10-24 1999-05-06 Christopher W. Mcdaniel Delivery vehicles for bioactive agents and uses thereof
GB2331924A (en) 1997-12-08 1999-06-09 Phares Pharm Res Nv Lipid compositions and their use
ES2216447T3 (es) * 1998-08-17 2004-10-16 Pfizer Products Inc. Composiciones proteicas estabilizadas.
US6159935A (en) 1999-11-29 2000-12-12 Pharmacia & Upjohn Co. Method for preventing diarrhea
IT1318539B1 (it) 2000-05-26 2003-08-27 Italfarmaco Spa Composizioni farmaceutiche a rilascio prolungato per lasomministrazione parenterale di sostanze idrofile biologicamente
AU2001283957A1 (en) 2000-07-27 2002-02-13 Novartis Ag Treatment of ocular disorders with somatostatin analogues
US20030049320A1 (en) * 2000-12-18 2003-03-13 Wockhardt Limited Novel in-situ forming controlled release microcarrier delivery system
CN1646171B (zh) 2002-04-19 2010-05-26 诺瓦提斯公司 新型生物材料、其制备和用途
US20040097419A1 (en) 2002-11-19 2004-05-20 Holger Petersen Organic compounds
GB0228571D0 (en) 2002-12-06 2003-01-15 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
PL1787658T3 (pl) 2012-08-31
EP1787658B1 (en) 2012-03-14
CY1112857T1 (el) 2016-04-13
ES2383303T3 (es) 2012-06-20
EP1787658A1 (en) 2007-05-23
ATE549011T1 (de) 2012-03-15
SI1787658T1 (sl) 2012-07-31
PT1787658E (pt) 2012-06-22

Similar Documents

Publication Publication Date Title
UY25148A1 (es) Método para producir una composición farmacéutica que comprende un análogo de ácido gama aminobutírico (gaba) y una droga antiinflamatoria no esteroide (nsaid)
NO341573B1 (no) Faste formuleringer av ospemifen og fremgangsmåte for fremstilling av ospemifen
ATE413865T1 (de) Zusammensetzungen mit alphahydroxy-säureester zur wirkstofffreisetzung und anwendungsverfahren dafür
AR054215A1 (es) Una formulacion farmaceutica de un taxano, una composicion solida de un taxano liofilizado a partir de una solucion de acido acetico, un procedimiento para la preparacion de dicha composicion solida de un taxano, una composicion solubilizante de un taxano liofilizado, y un conjunto de elementos (kit
ECSP034848A (es) Derivados oxazol acido carboxilico sustituidos para uso como activadores ppar-alpha y -gamma en el tratamiento de diabetes
CY1112333T1 (el) Φαρμακευτικο παρασκευασμα που περιεχει μια δραστικη ουσια πανω σε μια μητρα
BR0209320A (pt) ésteres de uridina farmaceuticamente ativos
CY1112857T1 (el) Φαρμακοτεχνικες μορφες παρατεταμενης απελευθερωσης αναλογου σωματοστατινης αναστολεων αναπτυξης ορμονης
NO20055601L (no) Farmasoytisk preparat i form av en hydrogel for transdermal administrasjon av aktive virkestoffer
AR029412A1 (es) Forma cristalina
WO2008093772A1 (ja) 経皮または経粘膜投与のためのアジュバントおよびこれを含む医薬製剤
NO20082181L (no) Formuleringer av Fispemifen
BR0112245B1 (pt) Éster de ácido 4-alcóxi-ciclohexano-1-amino-carboxílico
DK0796238T3 (da) Fremgangsmåde til stabilisering af polyumættede fedtsyrer og deres anvendelse i terapi og kosmetik
RS52735B (en) APPLICATION OF A COMBINATION CONTAINING L-CARNITINE OR ALKANOIL L-CARNITINE, OIL-SOLUBLE OIL-BENZOQUINON AND OMEGA-3-POLYESATURATED FATTY ACID FOR PREPARATION OF NUTRITION OR MEDICINAL PRODUCTS
AR051742A1 (es) Capsulas de lercanidipino
JP5048372B2 (ja) 育毛促進剤
AR048716A1 (es) Derivados de acido pentenoico, procedimientos para su preparacion, composiciones farmaceuticas que los comprenden y sus aplicaciones terapeuticas
CA2494503A1 (en) Treatment of multiple sclerosis with brain targeted anti oxidant compounds
PE20020903A1 (es) Metodo para prevenir la diarrea
RU2223947C2 (ru) ПРОИЗВОДНОЕ ФЕНИЛОВОГО ЭФИРА α-АМИНОКИСЛОТЫ
PT1178960E (pt) Analogos da vitamina d e sua utilizacao farmaceutica
UY27920A1 (es) Combinaciones de epinastina, pseudoefedrina y metilefedrina como nuevas formulaciones farmaceuticas
AR013538A1 (es) Nuevos mitogenos especificos de osteoblastos, metodos para prepararlos y drogas que contienen tales compuestos
AR047743A1 (es) Forma de dosificacion que comprende una prodroga de un inhibidor de bomba de proton, uso de una prodroga de sulfonilo de un inhibidor de la bomba de proton para preparar dicha forma de dosificacion y producto farmaceutico que la comprende